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AbstrAct:
MicroRNAs (miRNAs) are a class of small non-coding RNAs (ncRNAs) that regulate 
gene expression by repressing translation or triggering the degradation of 
complementary mRNA sequences. Certain miRNAs have been shown to function as 
integral components of the p53 and/or retinoblastoma (Rb) regulatory networks. 
As such, miRNA dysregulation can have a profound effect on cancer development. 
Previous studies have shown that miR-449a is down-regulated in human prostate 
cancer tissue and possesses potential tumor suppressor function. In the present 
study, we identify miR-449a-mediated growth arrest in prostate cancer cells is 
dependent on the Rb protein. We show that mutant Rb prostate cancer cells (DU-
145) are resistant to cell cycle arrest and cellular senescence induced by miR-
449a, while overexpression of wild-type Rb in DU-145 sublines (DU-1.1 and B5) 
restores miR-449a function. In silico analysis of 3’UTR regions reveal a putative 
miR-449a target site in the transcript of Cyclin D1 (CCND1); an oncogene involved 
in directly regulating Rb activity and cell cycle progression. Luciferase 3’UTR 
reporter  constructs  and  inhibitory  oligonucleotides  confirm  that  Cyclin  D1  is  a 
direct downstream target of miR-449a. We also reveal that miR-449a suppresses 
Rb phosphorylation through the knockdown of Cyclin D1 and previously validated 
target HDAC1. By targeting genes involved in controlling Rb activity, miR-
449a regulates growth and senescence in an Rb-dependent manner. These data 
indicate that miR-449a is a miRNA component of the Rb pathway and its tumor 
suppressor-like effects, in part, depends on Rb status in prostate cancer cells.
Abbreviations used: 3’UTR, 3’ untranslated region; HDACs, histone deacetylases
INtrODUctION
MicroRNAs (miRNAs) are a class of small non-
coding RNAs (ncRNAs) that function as key regulators of 
gene expression. By targeting complementary sequences 
in gene transcripts, miRNAs inhibit translation or degrade 
mRNAs to silence gene expression [1, 2]. Based on 
this function, miRNAs have been implicated in a wide 
range of cellular processes including cellular growth, 
differentiation, and disease [3].
Cancer is the result of a complex multistep process 
that involves the accumulation of sequential alterations of Oncotarget 2010; 1:  349 - 358 350 www.impactjournals.com/oncotarget
several genes. Retinoblastoma (Rb) protein is frequently 
mutated or inactivated in a broad range of cancer types 
to promote cell proliferation and survival. In prostate 
cancer, Rb inactivation is equally crucial for malignant 
transformation, which has been reported to be absent 
in as much as 60% of all lesions [4-6]. Mutations or 
overexpression of genes involved in suppressing Rb 
activity through hyperphosphorylation are also important 
components in cancer progression. For instance, 
constitutive activation of Cyclin D1 (CCND1) has been 
shown to promote Rb phosphorylation and cellular growth 
in numerous cancers including prostate cancer [7-9].
Aberrant miRNA expression is also linked to a 
number of human cancers [10]. Based on downstream 
targets, miRNAs can function as tumor suppressors 
and/or oncogenes. For instance, miR-34a is a tumor 
suppressor miRNA directly regulated by p53 [11]. It has 
proven to be an integral component of the p53 pathway 
Figure 1: Differential effects of mir-449a on cell cycle distribution in Pc-3 and DU-145 cells. A. PC-3 and DU-145 cells were 
transfected with 50 nM concentrations of miR-Con or miR-449a for 72 hours. Mock samples were transfected in the absence of miRNA. 
Floating and attached cells were collected, stained with PI, and processed for analysis by flow cytometry to measure DNA content. Shown are 
examples of resulting FL2A histograms. b. Flow cytometry data was analyzed to determine cell cycle distribution (G0/G1, S, and G2/M) in the 
surviving cell populations. c. Percentages of sub-diploid/apoptotic cells were calculated from entire gated whole-cell populations.Oncotarget 2010; 1:  349 - 358 351 www.impactjournals.com/oncotarget
by suppressing cell growth through targeting various 
oncogenes (i.e. MYCN, c-Met, etc.) [12, 13]. As such, the 
tumor suppressor activity of p53 has been directly linked 
to the growth inhibitory effects of miR-34a [14, 15]. 
It has been shown that miR-449a is depleted in human 
prostate tumor tissue relative to patient-matched controls 
and possesses tumor suppressor-like function, in part, 
through targeting HDAC1 and activating p27 expression 
[16]. In the present study, we indicate that the growth 
inhibitory function of miR-449a is largely dependent on 
Rb status in prostate cancer cells. Mutant Rb renders DU-
145 cells generally resistant to the growth inhibitory effects 
of miR-449a, while DU-145 sublines expressing wild-
type Rb retain sensitivity to miR-449a. The dependency 
on Rb is likely facilitated through miR-449a targeting 
genes involved in regulating Rb activity. In support, we 
define Cyclin D1 as another direct target suppressed by 
miR-449a in prostate cancer cells. We further indicate 
that miR-449a suppresses Rb phosphorylation through 
specific knockdown of both Cyclin D1 and HDAC1. Our 
data implicates miR-449a as a key miRNA component of 
the Rb pathway that functions to regulate prostate cancer 
cell growth, in part, by controlling Rb activity.
rEsULts
DU-145 cells are resistant to mir-449a-induced 
growth arrest and senescence
MicroRNA-449a is depleted in human prostate 
tumors and functions as a potential tumor suppressor 
miRNA by inhibiting proliferation and promoting 
apoptosis [16]. In order to further examine the 
physiological effects of miR-449a on prostate cancer cell 
growth, we transfected PC-3 (prostate adenocarcinoma) 
and DU-145 (prostate carcinoma) cells with miR-449a 
and evaluated cell cycle distribution by flow cytometry. 
Cells were also transfected with a non-specific miRNA 
(miR-Con) to serve as a control. In PC-3 cells, miR-449a 
caused G0/G1 arrest as indicated by the increase in G0/
G1 cell number and corresponding reductions in S and 
G2/M populations (Figure 1A-B). In contrast, cell cycle 
distribution in DU-145 cells was not significantly altered 
by miR-449a (Figure 1A-B). Further analysis of DNA 
fragmentation/apoptosis revealed a substantial increase 
in cells with sub-diploid DNA content; miR-449a caused 
~11% and ~13% boost in PC-3 and DU-145 apoptotic cell 
populations, respectively (Figure 1C). Although sensitive 
to the apoptotic effects of miR-449a, DU-145 cells are 
resistant to the inhibitory function of miR-449a on cell 
cycle progression. 
All cancer cells must circumvent cellular senescence 
in order to become immortal. General dysregulation of the 
cell cycle and key regulatory genes (i.e. p21, p16, etc.) 
can effectively promote a senescent-like phenotype in 
cancer cells [17-20]. Detection of senescence associated 
β-galactosidase (SA-β-gal) activity at pH 6.0 is a known 
biomarker for cellular senescence [21]. To evaluate miR-
449a-induced senescence in prostate cancer cell lines, we 
transfected PC-3 and DU-145 cells with miR-449a and 
stained for SA-β-gal activity. In a pattern similar to cell 
cycle analysis, PC-3 cells stained positive for SA-β-gal 
activity following miR-449a transfection, while staining 
in DU-145 cells was nearly undetectable in all treatments 
(Figure 2). These results further suggest that DU-145 cells 
are generally resistant to the growth arrest effects of miR-
449a.
rb sensitizes DU-145 sublines to growth arrest by 
mir-449a
Cellular senescence is primarily mediated by two 
proteins – p53 and retinoblastoma (Rb). Interestingly, 
neither PC-3 nor DU-145 cells express functional p53; 
however, wild-type Rb protein is expressed in PC-3 
cells [22, 23]. DU-145 cells possess a loss-of-function 
Figure 2: DU-145 cells are resistant to mir-449a-induced cellular senescence.  PC-3 and DU-145 cells were transfected with 
50 nM concentrations of miR-Con or miR-449a for 72 hours.  Cells were fixed in formaldehyde and stained for SA-β-gal activity overnight.   
Images were captured by phase contrast microscopy at 200X magnification.  Dark perinuclear staining marks senescent cells.Oncotarget 2010; 1:  349 - 358 352 www.impactjournals.com/oncotarget
mutation that yields a truncated Rb protein [23]. To 
determine if wild-type Rb can sensitize DU-145 cells 
to miR-449a, we obtained two DU-145 sublines that 
stably overexpress wild-type Rb from either a plasmid 
vector (DU-1.1) or retroviral construct (B5). As shown 
in Figure 3A, detection of Rb protein was validated by 
immunoblot analysis. Both DU-1.1 and B5 cells express 
wild-type Rb at levels comparable to PC-3 cells, while 
DU-145 cells express low-levels of a slightly truncated 
form of Rb. We subsequently transfected both DU-1.1 
and B5 cells with miR-449a and examined cell cycle 
distribution by flow cytometry. As shown in Figure 3B, 
miR-449a caused G0/G1 arrest in DU-1.1 and B5 cells 
as indicated by the increase in G0/G1 cell number and 
concurrent declines in S and G2/M populations. Rb also 
enhanced the apoptotic effects of miR-449a; sub-diploid/
apoptotic populations increased to as much as ~45% 
and ~30% in DU-1.1 and B5, respectively (Figure 3C). 
Because standard miR-449a transfection concentrations 
(50 nM) resulted in robust levels of cell death, DU-1.1 
and B5 cells were also transfected at lower concentrations 
(10 and 25 nM) of miR-449a to increase viable cell 
Figure 3: Wild-type rb sensitizes DU-1.1 and b5 cells to mir-449a-mediate cell cycle arrest.  A.  Protein extracts were prepared 
from PC-3, DU-145, DU-1.1, and B5 cell lines and resolved on SDS polyacrylamide gels.  Total Rb and GAPDH were detected by immunoblot 
analysis in each cell line.  GAPDH served as a loading control.  Note DU-145 cells express low levels of a slightly truncated form of Rb.  b. 
DU-1.1 and B5 cells were transfected with mock, miR-Con, or miR-449a for 72 hours as indicated.  Floating and attached cells were collected, 
stained with PI, and processed for analysis by flow cytometry to measure DNA content.  Data was analyzed to determine cell cycle distribution 
(G0/G1, S, and G2/M) in the surviving cell populations.  Lower concentrations of miR-449a improved cell cycle analysis by increasing viable 
cell number.  c. Percent sub-diploid/apoptotic cells were calculated from entire gated whole-cell populations.Oncotarget 2010; 1:  349 - 358 353 www.impactjournals.com/oncotarget
number. Note improvement in cell quantity within the 
cell cycle fraction at lower concentrations of miR-449a 
in  the  FLA2  histograms  (Supplementary  Figure  1).  10 
and 25 nM treatments reduced the apoptotic cell fractions 
and improved cell cycle analysis of DU-1.1 and B5 cells 
(Figure 3B-C). Collectively, these results indicate that 
wild-type Rb sensitizes DU-145 sublines to miR-449a-
induced growth arrest, as well as further enhances the 
apoptotic effects of miR-449a.
To determine if DU-1.1 and B5 cells have also 
become sensitive to miR-449a-induced senescence, we 
transfected DU-145 sublines with miR-449a and stained 
for SA-β-gal activity. At 10 and 25 nM concentrations, 
DU-1.1 and B5 cells stained positive for SA-β-gal, while 
staining in mock and miR-Con treatments were nearly 
undetectable (Figure 4). This data indicates that miR-449a 
triggered a senescent-like phenotype in both DU-145 
sublines.
DuPro (prostate adenocarcinoma) cells are also wild-
type for Rb [22, 24]. Transfection of miR-449a promoted 
cell cycle arrest at G1/G0, increased sub-diploid/apoptotic 
populations, and caused SA-β-gal staining to indicate that 
DuPro cells are also sensitive to miR-449a (Supplementary 
Figure 2A-D). This data further supports that miR-449a 
induces growth arrest via an Rb-dependent mechanism in 
prostate cancer cells.
mir-449a targets cyclin D1
Because Rb is required, in part, for the tumor 
suppressor-like function of miR-449a in prostate cancer 
cells, miR-449a likely targets genes responsible for 
regulating Rb activity. Cyclin D1 functions in conjunction 
with CDK4/6 to directly regulate Rb phosphorylation 
and promote entry into S phase of the cell cycle [8]. As 
shown in Figure 5A, in silico analysis revealed a putative 
target site in the 3’UTR of the Cyclin D1 (CCND1) 
transcript. Because all modes of miRNA-mediated gene 
repression result in decreased target protein, we evaluated 
Cyclin D1 levels by immunblot analysis. As shown in 
Figure  5B,  miR-449a  significantly  reduced  Cyclin  D1 
protein levels in PC-3 cells. To confirm Cyclin D1 is a 
direct target of miR-449a, we cloned the putative target 
sequence into the 3’UTR of a luciferase reporter vector 
(CCND1-WT). A scrambled target site (CCND1-MUT) 
was also constructed as a control for sequence specificity. 
Co-transfection with miR-449a reduced the luciferase 
activity of CCND1-WT, whereas the Cyclin D1 mutant 
construct (CCND1-MUT) was protected from miR-449a-
mediated repression (Figure 5C). We also co-treated cells 
with a complementary oligonucleotide (anti-miR-449a) 
designed  to  specifically  bind  and  sequester  miR-449a 
activity. Although transfection of a non-specific control 
oligonucleotide (anti-miR-Con) did not interfere with 
the miR-449a-mediated repression of CCND1-WT, anti-
miR-449a blocked miR-449a function causing a rebound 
in CCND1-WT luciferase activity (Figure 5C). Taken 
together, this data indicates that the Cyclin D1 transcript 
is a direct target of miR-449a.
Conservation of miRNA and target site sequence 
across multiple species is considered supporting 
evidence for authentic miRNA-target interactions [25]. 
Interestingly, miR-449a has already been established as 
an evolutionary conserved miRNA [16]. We performed an 
additional in silico analysis on the Cyclin D1 3’UTR and 
identified the miR-449a target site as a highly-conserved 
sequence found in many vertebrates (i.e. human, horse, 
lizard,  etc.)  (Supplementary  Figure  3).  This  highlights 
an  evolutionary  significance  for  the  target  site  and 
corroborates the functional interaction between the Cyclin 
D1 transcript and miR-449a.
mir-449a regulates rb phosphorylation by 
Figure 4: mir-449a triggers cellular senescence in DU-1.1 and b5 cells.  DU-1.1 and B5 cells were transfected with mock, miR-
Con, or miR-449a for 72 hours.  Transfection of miR-449a at 10 or 25 nM concentrations improved cell density for analysis.  Cells were fixed 
in formaldehyde and stained for SA-β-gal activity overnight.  Images were captured by phase contrast microscopy at 200X magnification.  Dark 
perinuclear staining marks senescent cells.Oncotarget 2010; 1:  349 - 358 354 www.impactjournals.com/oncotarget
targeting cyclin D1 and HDAc1
Hyperphosphorylation of Rb promotes cell cycle 
progression and cell growth [26, 27]. To determine if miR-
449a regulates Rb activity, we evaluated Rb phosphorylation 
by immunoblot analysis following knockdown of Cyclin 
D1. We transfected PC-3 cells with miR-449a or a specific 
siRNA designed to target only Cyclin D1 (siCCND1). As 
shown in Figure 6A, knockdown of Cyclin D1 by miR-
449a or siCCND1 drastically reduced phophorylated Rb 
(P-Rb) levels. This data indicates that miR-449a regulates 
Rb phosphorylation, in part, through targeted knockdown 
of Cyclin D1.
Cell cycle inhibitory protein p27 also functions to 
regulate Rb phosphorylation by inhibiting cyclin dependent 
kinase (CDK) activity [28]. It has previously been shown 
that miR-449a activates p27 expression by targeted 
knockdown of HDAC1 in prostate cancer cells [16]. To 
determine if miR-449a can also modulate Rb activity 
through HDAC1, we transfected PC-3 cells with miR-
449a or a specific siRNA targeting HDAC1 (siHDAC1) 
and detected Rb phosphorylation by immunoblot analysis. 
As shown in Figure 6B, knockdown of HDAC1 by miR-
449a or siHDAC1 elevated p27 protein and reduced P-Rb 
levels. This data indicates that miR-449a also regulates 
Rb phosphorylation though knockdown of HDAC1. 
DIscUssION
We provide evidence that the putative tumor 
suppressor function of miR-449a is, in part, dependent on 
Rb in prostate cancer cells. DU-145 cells devoid of wild-
type Rb are resistant to cell cycle arrest and senescence 
Figure 5: mir-449a targets cyclin D1.  A. The 3’UTR of 
the Cyclin D1 transcript contains a putative miR-449a target site.   
Indicated is complementary base-pairing, including G:U wobbles, 
between the mature miR-449a guide sequence and the Cyclin D1 
target site.  b. PC-3 cells were transfected with mock, miR-Con, or 
miR-449a for 72 hours as indicated.  Cyclin D1 and GAPDH protein 
levels were evaluated by immunoblot analysis using protein-specific 
antibodies.  GAPDH served as a loading control.  c. Putative miR-
449a target sequence from Cyclin D1 (CCND1-WT) was cloned 
into the 3’UTR of a luciferase reporter vector.  A scrambled target 
site (CCND1-MUT) was also constructed as a control for sequence 
specificity.    Constructs  were  co-transfected  with  a  β-galactosidase 
expression vector and treated with miR-449a for 24 hrs.  Luciferase 
activity  was  accessed  and  normalized  to  β-galactosidase  activity.   
Cells were also co-treated with a miR-449a inhibitory oligonucleotide 
(anti-miR-449a) or a non-specific control (anti-miR-Con) to confirm 
reduction in luciferase activity was dependent on miR-449a sequence.
Figure 6:  mir-449a regulates rb phosphorylation by 
targeting cyclin D1 and HDAc1.  A. PC-3 cells were transfected 
at 50 nM concentrations of miR-Con, miR-449a, or siCCND1 for 72 
hours.  Mock samples were transfected in the absence of miRNA/
siRNA.  Cyclin D1, phosphorylated Rb (P-Rb), total Rb, and GAPDH 
protein levels were evaluated by immunoblot analysis using protein-
specific antibodies.  b. PC-3 cells were transfected with mock, miR-
Con, miR-449a, or siHDAC1 for 72 hours as indicated.  HDAC1, 
p27, P-Rb, total Rb, and GAPDH protein levels were evaluated by 
immunoblot analysis.  GAPDH served as a loading control.   Oncotarget 2010; 1:  349 - 358 355 www.impactjournals.com/oncotarget
induced by miR-449a. Only upon restoration of Rb did 
miR-449a regain its growth inhibitory effects in the DU-
145 sublines. Based on our data, a simple model can be 
created linking miR-449a to Rb activation and growth 
arrest in prostate cancer cells (Figure 7). We show that 
miR-449a can regulate Rb phosphorylation by directly 
targeting Cyclin D1 and HDAC1. Modulation of Rb 
activity through HDAC1 knockdown is likely facilitated 
through downstream targets such as the activation of p27 
expression. Interestingly, p27 directly binds cyclins (e.g. 
Cyclin D1) and inhibits CDK4/6 complex activity [28]. 
By this mechanism, miR-449a has a dual approach for 
regulating Cyclin D1 activity and Rb phosphorylation.
It has also been reported that miR-449a directly 
targets and represses the expression of CDK6 and 
CDC25A; two more key factors involved in promoting 
Rb phosphorylation [29]. Further evidence has indicated 
that miR-449a is also transcriptionally regulated by E2F 
transcription factors [29-31]. E2F proteins preferentially 
interact with hypophosphorylated Rb, which sequesters 
their activity. Upon Rb phosphorylation, E2F proteins are 
released to activate downstream gene expression. Because 
E2F family members function as downstream mediators 
of Rb, miR-449a functions in an auto-regulatory loop 
to control Rb activity by targeting multiple upstream 
regulatory factors (i.e. Cyclin D1, HDAC1, CDK6, and 
CDC25B). Collectively, these reports, in combination 
with  our  data,  define  miR-449a  as  an  integral  miRNA 
component of the Rb pathway. 
Phenotypically, miR-449a is a multifaceted miRNA 
in that it induces apoptosis in association to cell cycle 
arrest [16, 30]. However, we reveal that miR-449a 
promotes apoptosis in prostate cancer cells regardless of 
Rb status; both PC-3 and DU-145 cells are susceptible 
to the apoptotic effects of miR-449a. Previous research 
has  indicated  that  the  specific  knockdown  of  HDAC1 
contributes to the apoptotic effects of miR-449a [16]. 
Because HDACs regulate numerous downstream factors 
including apoptotic genes (i.e. Bcl-XL, etc.), miR-449a 
may promote apoptosis in an Rb-independent manner 
through depletion of HDAC1 [32, 33]. In addition, miR-
449a may also directly target and suppress the expression 
of antiapoptotic genes. For instance, in silico analysis 
utilizing the miRanda algorithm reveals a putative target 
site in the 3’UTR of the BCL2 transcript [25]. We also 
reveal that wild-type Rb enhanced the apoptotic response 
in DU-145 sublines to suggest that miR-449a may facilitate 
apoptosis through Rb-dependent mechanisms, as well. 
In support, Rb activation is known to trigger apoptosis 
by sequestering E2F protein activity and repressing the 
expression of downstream antiapoptotic gene BIRC5/
survivin [34].
Precise control of Rb activity is absolutely essential 
for maintaining regulated cellular growth. In nearly all 
cancer types Rb is inactivated to promote oncogenesis. We 
propose that the loss of miR-449a expression can promote 
Rb inactivation and prostate cancer progression. In vivo 
analysis has shown that miR-449a is depleted in human 
prostate tumor tissue relative to patient-matched controls 
[16]. Furthermore, miR-449a is located in a chromosomal 
region previously identified as a susceptibility locus in 
a variety of malignancies including prostate cancer [35, 
36]. The mechanism by which miR-449a is depleted in 
prostate cancer may result from genomic deletion or 
epigenetic silencing. Co-treatment of histone methylation 
and HDAC inhibitors has been shown to re-activate miR-
449a expression in breast cancer cells [29]. Regardless, 
loss of miR-449a would disrupt its auto-regulatory control 
over Rb and promote unregulated growth, which may, in 
part, contribute to transformation during prostate cancer 
tumorigenesis. Our data supports the tumor suppressor-
like function of miR-449a by highlighting its relationship 
with Rb and describing its inhibitory effects on cell 
growth. Although miR-449a-mediated cell cycle arrest 
is largely Rb-dependent, re-activation or replacement of 
miR-449a may have therapeutic benefit in prostate cancer 
that retains functional Rb status.
MAtErIAL AND MEtHODs
cell culture and mirNA/sirNA transfection
PC-3, DU-145, DuPro, DU-1.1, and B5 cells were 
maintained in RPMI 1640 medium supplemented with 
10% FBS, L-glutamine (2 mM), penicillin (100 U/ml) and 
streptomycin (100 µg/ml) in a humidified atmosphere of 
5% CO2 at 37°C. DU-1.1 and B5 are well characterized 
DU-145 sublines engineered to express wild-type Rb 
protein [23, 37]. The day before transfection, cells were 
plated in growth medium without antibiotics at a density 
of ~50-60%. Transfection of miRNA/siRNA was carried 
out using Lipofectamine RNAiMax (Invitrogen, Carlsbad, 
CA) according to the manufacturer’s instructions for 72 
hours. The mature hsa-miR-449a mimic (miR-449a), 
Figure 7:  A model linking mir-449a to rb activation and 
growth arrest in prostate cancer cells.  Direct downstream 
targets of miR-449a are shown in red, while miR-449a is colored blue.   
miR-449a-mediated depletion of Cyclin D1 and/or HDAC1 reduces 
Rb phosphorylation leading to growth arrest (denoted in red type).Oncotarget 2010; 1:  349 - 358 356 www.impactjournals.com/oncotarget
non-specific control (miR-Con), Cyclin D1 (siCCND1) 
and HDAC1 (siHDAC1) siRNAs were synthesized 
by Invitrogen. All duplexes contained 2-nucleotide 3’ 
overhangs. Sequences are listed in Supplementary Table 
1.
Analysis of cell cycle distribution and apoptosis 
by flow cytometry.
Transfected cells were trypsinized and centrifuged 
at 2000×g for 5 min at 4°C in complete medium. Cell 
pellets were resuspended in 1 ml of cold saline GM 
solution (6.1 mM glucose, 1.5 mM NaCl, 5.4 mM KCl, 
1.5 mM Na2HPO4, 0.9 mM KH2PO4, 0.5 mM EDTA) 
and fixed in 3 ml of 100% ethanol overnight at 4°C. Cells 
were then washed once in PBS containing 5 mM EDTA, 
centrifuged at 2000×g for 5 min, and resuspended in 1 ml 
of propidium iodide (PI) staining solution (30 µg/ml PI, 
300 µg/ml RNase A in PBS). Cells were stained for 1 hour 
at room temperature in the dark and subsequently filtered 
through 30 µm nylon mesh. Analysis was performed on a 
FACSCalibur flow cytometer (Becton Dickinson, Franklin 
Lakes, NJ). A total of 10,000 events were collected and PI 
intensity was analyzed using the FL2 channel for relative 
DNA content. Forward and side scatter gates and a 
doublet discrimination plot were set to include whole and 
individual cell populations, respectively. The resulting 
data was analyzed to determine cell cycle distribution and 
sub-diploid/apoptotic cell fraction. Markers were placed 
to quantify the percentage of cells in sub-diploid, G0/G1, 
S, and G2/M populations.
Senescence-associated β-galactosidase (SA-β-gal) 
staining.
PC-3, DU-145, DuPro, DU-1.1, and B5 cell lines 
were transfected with miR-449a for 72 hours and stained 
for SA-β-gal activity as previously described [21]. Briefly, 
cells were washed with PBS, fixed in 3% formalhehyde 
for 10 min at room temperature, and incubated overnight 
at  37°C  in  SA-β-gal staining reagent (1 mg/ml of 
X-Gal, 5 mM potassium ferrocyanide, 5 mM potassium 
ferricyanide, 150 mM NaCl, and 2 mM MgCl2, 40 mM 
citric acid/sodium phosphate, pH 6.0). Cell images were 
taken at 200× magnification by phase contrast microscopy.
Immunoblotting
Cultured  cells  were  washed  with  cold  PBS  and 
lysed with M-PER protein extraction buffer (Pierce, 
Rockford, IL) containing protease inhibitors. Cell lysates 
were centrifuged and supernatants were collected. Equal 
quantities of protein were resolved by electophoresis on 
sodium  dodecyl  sulfate  (SDS)  polyacrlamide  gels  and 
transferred to 0.45 µm nitrocellulose membranes by 
voltage gradient. The resulting blots were blocked with 
5% non-fat dry milk and probed with primary antibodies 
specific to Rb (Cell Signaling, Danvers, MA), P-Rb (BD 
Transduction, Franklin Lakes, NJ), HDAC1 (Santa Cruz 
Biotechnology, Santa Cruz, CA), p27 (BD Transduction), 
or GAPDH (Chemicon, Temecula, CA). Immunodetection 
occurred by incubating blots with appropriate secondary 
HRP-linked antibodies and utilizing chemiluminescence 
to visualize the antigen-antibody complexes. GAPDH 
served as an internal control.
3’Utr constructs/luciferase assay
Complementary oligonucleotides containing the 
putative miR-449a target site from Cyclin D1 (CCND1-
WT) was cloned into the 3’UTR of the pMIR-Report 
luciferase reporter vector (Applied Biosystems, Foster City, 
CA). A scrambled target site (CCND1-MUT) designed to 
interfere with seed sequence recognition was also cloned 
to serve as a control for specificity. All oligonucleotide 
sequences used to create the 3’UTR constructs are listed 
in Supplementary Table 1. PC-3 cells were transfected 
with 0.6 µg CCND1-WT or CCND1-MUT construct, 
0.4 µg pMIR-Report Beta-gal, and 30 nM miR-449a for 
24 hours. The pMIR-Report Beta-gal vector served as a 
control to monitor transfection efficiency. Treatment with 
miR-449a anti-miR inhibitory oligonucleotide (anti-miR-
449a) or anti-miR negative control (anti-miR-Con) from 
Applied Biosystems was also utilized to sequester miR-
449a activity and validate sequence specificity. The Dual-
Light  System®  chemiluminescent  reporter  gene  assay 
(Applied Biosystems) was used to quantify luciferase and 
β-galactosidase activity.
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